Non-executive Director Appointment
News Dec 05, 2015
ReNeuron Group plc has announced the appointment of Dr Mike Owen as a Non-executive Director of the Company with immediate effect. He will also chair the Company’s Scientific Advisory Board.
Dr Owen’s career in biotech, the pharmaceutical industry and academia spans almost 40 years. He was formerly Senior Vice President for Biopharmaceuticals Research at GlaxoSmithKline where he was responsible for the discovery and development of antibody drugs in multiple therapeutic areas through to successful clinical proof of concept. He was also a Founder and Chief Scientific Officer of Kymab Ltd, an antibody-based biotech company, and for many years held a research position at the Imperial Cancer Research Fund (now CR-UK).
He currently serves as a director of Zealand Pharma, Ossianix Inc, BliNK Biomedical SAS and Avacta plc and is a member of the Scientific Advisory Boards of Kymab Ltd and the CRT Pioneer Fund LP, and the investor advisory board of HS Lifesciences gmbh. He is a Fellow of the Academy of Medical Sciences and a member of the European Molecular Biology Organization.
Commenting on Dr Owen’s appointment, John Berriman, Chairman of ReNeuron, said: “I am delighted to welcome Mike to the Board of the Company, and to its Scientific Advisory Board. As a consultant he has already provided much valuable input to the Company’s research and development programmes and this, together with his broad experience in progressing cutting edge research projects from the bench to the clinic, makes us confident that this appointment will lead to a significant further strengthening of our Board.”
Dr Owen commented: “I am delighted to have joined the Board of ReNeuron, and its Scientific Advisory Board, and look forward to helping the Company to realize the potential of its stem cell and related technologies to generate innovative new medicines for diseases of unmet medical need.”
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.